Principal oncogenic signal transduction in melanoma often engages Ras/MAPK activation and can co-involve, or recruit, dysregulated PI3K/AKT/mTOR signaling that can serve as a source of resistance to MAPK inhibition, including in the case of human and canine MM [4,23,50]. The gene discussed is AKT1; the disease is Miyoshi myopathy.